Proton Therapy for Anal Cancer
Trial Summary
What is the purpose of this trial?
This trial is testing if Proton Therapy can reduce radiation exposure to healthy areas around anal cancer, aiming to lessen side effects compared to standard treatments. Proton therapy is an emerging treatment for cancer that may have distinct advantages over conventional radiotherapy, particularly in minimizing radiation dose to surrounding normal tissue.
Research Team
Jordan Kharofa, MD
Principal Investigator
University of Cincinnati
Eligibility Criteria
This trial is for individuals with a specific type of anal cancer (squamous or basaloid carcinoma) that's at a certain stage (T2-4, any N category). Participants must be relatively active and able to care for themselves (Karnofsky Performance Status >70%). Those expected to live less than 3 months cannot join.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive standard chemoradiation using 5-FU, Mitomycin, with pencil beam proton radiotherapy
Follow-up
Participants are monitored for safety and effectiveness after treatment
Quality of Life Assessment
Utilization of the Patient Reported Outcomes- Common Toxicity Criteria for Adverse Events at pretreatment and up to 12 months
Treatment Details
Interventions
- Chemotherapy
- Proton therapy
Chemotherapy is already approved in European Union, United States, Canada, Japan, China, Switzerland for the following indications:
- Breast cancer
- Metastatic breast cancer
- Various other cancers
- Breast cancer
- Metastatic breast cancer
- Various other cancers
- Breast cancer
- Metastatic breast cancer
- Various other cancers
- Breast cancer
- Metastatic breast cancer
- Various other cancers
- Breast cancer
- Metastatic breast cancer
- Various other cancers
- Breast cancer
- Metastatic breast cancer
- Various other cancers
Find a Clinic Near You
Who Is Running the Clinical Trial?
Jordan Kharofa
Lead Sponsor